Jean B. Belasco

Hematology | Oncology

3401 Civic Center Blvd
Philadelphia, PA 19104

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.

Vinblastine/Methotrexate for Debilitating and Progressive Plexiform Neurofibroma in Children and Young Adults with Neurofibromatosis Type 1: A Phase 2 Study.

Journal: Cancers

Published: March 22, 2023

A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma.

A Pilot Study of Low-Dose Craniospinal Irradiation in Patients With Newly Diagnosed Average-Risk Medulloblastoma.

Journal: Frontiers in oncology

Published: July 20, 2021

MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus.

MRI for Response Assessment of Extensive Lymphatic Malformations in Children Treated With Sirolimus.

Journal: AJR. American journal of roentgenology

Published: January 06, 2021

Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation.

Severe Lymphatic Disorder Resolved With MEK Inhibition in a Patient With Noonan Syndrome and SOS1 Mutation.

Journal: Pediatrics

Published: April 09, 2020

Risk of brainstem necrosis in pediatric patients with central nervous system malignancies after pencil beam scanning proton therapy.

Risk of brainstem necrosis in pediatric patients with central nervous system malignancies after pencil beam scanning proton therapy.

Journal: Acta oncologica (Stockholm, Sweden)

Published: September 13, 2019

Tumor bed proton irradiation in young children with localized medulloblastoma.

Tumor bed proton irradiation in young children with localized medulloblastoma.

Journal: Pediatric blood & cancer

Published: April 17, 2019

ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.

ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.

Journal: Nature medicine

Published: May 08, 2018

Primary lymphedema and other lymphatic anomalies are associated with 22q11.2 deletion syndrome.

Primary lymphedema and other lymphatic anomalies are associated with 22q11.2 deletion syndrome.

Journal: European journal of medical genetics

Published: October 06, 2017

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Journal: The New England journal of medicine

Published: December 29, 2016

Medulloblastoma With Obstructive Hydrocephalus in a Young Infant.

Medulloblastoma With Obstructive Hydrocephalus in a Young Infant.

Journal: Pediatric emergency care

Published: November 12, 2015

Premature Epiphyseal Closure of the Lower Extremities Contributing to Short Stature after cis-Retinoic Acid Therapy in Medulloblastoma: A Case Report.

Premature Epiphyseal Closure of the Lower Extremities Contributing to Short Stature after cis-Retinoic Acid Therapy in Medulloblastoma: A Case Report.

Journal: Hormone research in paediatrics

Published: July 17, 2015

Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.

Phase I study of temozolomide in combination with thiotepa and carboplatin with autologous hematopoietic cell rescue in patients with malignant brain tumors with minimal residual disease.

Journal: Bone marrow transplantation

Published: July 05, 2015

Showing 1-12 of 18

Last Updated: 09/26/2026